JPMorgan Chase & Co. Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $44.00
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price objective reduced by JPMorgan Chase & Co. from $45.00 to $44.00 in a report released on Friday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Several other analysts have also recently weighed in on the stock. Canaccord Genuity Group dropped their […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price objective reduced by JPMorgan Chase & Co. from $45.00 to $44.00 in a report released on Friday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Several other analysts have also recently weighed in on the stock. Canaccord Genuity Group dropped their […]
